Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Intangibles: 2023-2025

Historic Intangibles for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to $10.4 million.

  • BioLineRx's Intangibles fell 23.97% to $10.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $10.4 million, marking a year-over-year decrease of 23.97%. This contributed to the annual value of $10.4 million for FY2024, which is 29.66% down from last year.
  • Latest data reveals that BioLineRx reported Intangibles of $10.4 million as of Q2 2025, which was down 0.22% from $10.4 million recorded in Q1 2025.
  • In the past 5 years, BioLineRx's Intangibles ranged from a high of $14.9 million in Q4 2023 and a low of -$179,000 during Q3 2023.
  • In the last 3 years, BioLineRx's Intangibles had a median value of $10.4 million in 2024 and averaged $8.7 million.
  • Data for BioLineRx's Intangibles shows a peak YoY increase of 14,728.87% (in 2024) and a maximum YoY decrease of 29.66% (in 2024) over the last 5 years.
  • BioLineRx's Intangibles (Quarterly) stood at $14.9 million in 2023, then decreased by 29.66% to $10.4 million in 2024, then dropped by 23.97% to $10.4 million in 2025.
  • Its last three reported values are $10.4 million in Q2 2025, $10.4 million for Q1 2025, and $10.4 million during Q4 2024.